NOGA Therapeutics Webinar
The gene therapy landscape is undergoing a monumental paradigm shift. Rather than extracting cells, engineering them in a lab (Ex-Vivo), and re-infusing them into patients, groundbreaking technologies now enable precise, long-lasting In-Vivo genetic reprogramming directly inside the patient's body.
NOGA Therapeutics is leveraging this revolution to build a broad In-Vivo platform targeting severe, life-threatening genetic immunodeficiencies, with a vision to create one-time curative treatments that scale to common diseases.
Join us for an exclusive investor-focused webinar providing an inside look into NOGA's technology, pipeline, and strategic trajectory toward the US public markets.
What We Will Cover
🔬 The Technology & Vision: Transitioning from Ex-Vivo clinical development to the future of In-Vivo cell programming.
📊 Pre-Clinical Highlights: Key data and progress on our lead programs in collaboration with the NIH.
🇺🇸 US Capital Markets Strategy: Our current bridge round and the path toward the U.S. capital market.
💬 Interactive Q&A: Get your questions answered directly by the presenters.
Featured Speakers
Dr. Noam Diamant | Co-Founder & CEO, NOGA Therapeutics
Biotech entrepreneur and leader in advanced therapies with extensive experience founding companies, securing capital, and executing a $300M exit in the gene therapy field.
Dr. Peter Kash | Board Member, NOGA Therapeutics
Co-Founder and Chairman of Camelot BioCapital.
A four-decade veteran of the biotechnology industry, he has co-founded more than a dozen companies that have collectively raised over $1 billion and reached a combined peak market value of approximately $20 billion. These companies have produced seven FDA approved drugs. He has also served as a Visiting Adjunct Professor at Wharton and Visiting Professor at Nihon University in Tokyo and the Hebrew University of Jerusalem.
Dr. Gavin Samuels | Managing Director, Rodman & Renshaw
Biotech investment banking leader with 20+ years of healthcare experience, including executive roles at Pfizer, Teva, Merck, and Lonza. He helped to build CinCor Pharma (acquired by AstraZeneca for $1.8B).
Who Should Attend?
This webinar is tailored for private investors, family offices, biotech angel investors, and venture partners interested in cutting-edge advanced therapies and high-growth healthcare opportunities.